Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.50 |
| ▸ | APEX1 | P27695 | 1/20 | 0.49 |
| ▸ | CCR1 | P32246 | 1/20 | 0.48 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26188327 | 0.89 | ALDH1A1 (0.55) | NPC1ALDH1A1KDM4ESMN1; SMN2MEN1 | |
| SCHEMBL24254492 | 0.85 | NPC1 (0.61) | NPC1ALDH1A1KDM4ESMN1; SMN2MEN1 | |
| SCHEMBL26188331 | 0.85 | NPC1 (0.53) | NPC1ALDH1A1KDM4ESMN1; SMN2MEN1 | |
| SCHEMBL15276206 | 0.79 | KMT2A (0.56) | NPC1MEN1KMT2AHCRTR1APEX1 | |
| SCHEMBL24254576 | 0.79 | KMT2A (0.51) | NPC1MEN1KMT2AHCRTR1APEX1 | |
| SCHEMBL15276210 | 0.76 | APEX1 (0.58) | NPC1SMN1; SMN2MEN1KMT2AHCRTR1 | |
| Hydrochloric Acid SCHEMBL1014557 | 0.76 | CCR1 (0.49) | NPC1ALDH1A1KDM4ESMN1; SMN2MEN1 | |
| SCHEMBL26188049 | 0.76 | ALDH1A1 (0.64) | ALDH1A1KDM4ESMN1; SMN2MEN1KMT2A | |
| SCHEMBL25045867 | 0.74 | HPGD (0.60) | ALDH1A1KDM4ESMN1; SMN2MEN1KMT2A | |
| SCHEMBL11817253 | 0.73 | PTPRG (0.52) | NPC1SMN1; SMN2MEN1KMT2ACA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230271918-A1 | SUBSTITUTED 3-AMINO-4-METHYLBENZENESULFONAMIDES AS SMALL MOLECULE INHIBITORS OF UBIQUITIN-SPECIFIC PROTEASE 28 | DANA-FARBER CANCER INSTITUTE, INC. | 2023-08-31 | — | — | US | disclosed |
| WO-2022035804-A1 | SUBSTITUTED 3-AMINO-4-METHYLBENZENESULFONAMIDES AS SMALL MOLECULE INHIBITORS OF UBIQUITIN-SPECIFIC PROTEASE 28 | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2022-02-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230271918-A1 | SUBSTITUTED 3-AMINO-4-METHYLBENZENESULFONAMIDES AS SMALL MOLECULE INHIBITORS OF UBIQUITIN-SPECIFIC PROTEASE 28 | USP28, USP30, USP1 | NPC1 2293/4885ALDH1A1 1387/4885KDM4E 290/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.